Effect of vascular endothelial growth factor A in PROX1 silenced colorectal cancer xenografts by Pyöriä, Lari
  
 
 
 
Effect of vascular endothelial growth factor A in PROX1 
silenced colorectal cancer xenografts 
 
 
 
 
 
Lari Pyöriä 
Bachelor of Medicine 
Translational Cancer Biology 
Research Program 
Faculty of Medicine 
University of Helsinki 
 
 
 
 
 
Helsinki 05.09.2014 
Tutkielma 
Supervisors: Dr. Kari Alitalo, MSc Ville Hyvönen 
Faculty of Medicine 
University of Helsinki  
lari.pyoria@helsinki.fi 
 
 i 
  
 
– Faculty 
 Faculty of Medicine 
– Department 
 Institute of Biomedicine 
– Author 
 Lari Pyöriä 
– Title 
Effect of vascular endothelial growth factor A in PROX1 silenced colorectal cancer 
xenografts 
– Subject 
 Medicine 
Työn laji  Arbetets art – Level 
 Tutkielma 
– Month and year 
 05.09.2014 
-Sidoantal - Number of 
pages 
 30 
– Abstract 
 
In our research we studied if the overexpression of VEGF-A would save the 
impaired tumor growth in PROX1 silenced colorectal cancer xenografts.  
 
We conducted both small hairpin PROX1 and VEGF-A gene transfers to 
SW1222 colorectal cancer cells using lentiviral vectors. SW1222 cell lines were 
then injected to Nod scid gamma mice and grown for 14 days for analysis. 
 
We also established 3D cocultures of genetically modified SW1222 cell line 
together with lymphatic endothelial cells or blood endothelial cells to analyze 
lymphangiogenesis and angiogenesis in vitro. 
 
We found out that overexpression of VEGF-A rescues the growth of PROX1 
silenced tumors. Large necrotic areas in the central of the PROX1 silenced 
tumors remain even though VEGF-A overexpression induces greater vascularity 
in these xenografts.  
 
In 3D cocultures silencing of PROX1 did not affect in vitro lymphangiogenesis or 
angiogenesis. (135)  
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1 Introduction 
 
 
The host laboratory has previously shown by histological and 
immunohistochemical methods that silencing of PROX1 in colorectal cancer 
(CRC) xenografts implanted ectopically into mouse increased apoptosis in the 
hypoxic tumor core. However, the tumor periphery continues to thrive. (49) The 
aim of our study was to see if vascular endothelial growth factors (VEGFs) 
could compensate for the loss of PROX1 in colorectal cancer cell progression in 
vivo and in vitro.   
 
An outline of study objectives 
 
The first objective was to transfer VEGF-C or VEGF-A gene to CRC cells 
(SW1222 cell line) to obtain their overexpression. Afterwards the CRC cells 
were introduced with lentiviral shPROX1 or SCR short hairpin RNA construct to 
establish PROX1-silencing in that cell line.  After successful gene transfer, the 
cells were cultured in order to have enough cells  (1.5 x 10 exp6) for mouse 
xenograft transplants.  
 
The examined cell lines were injected into the skin of NOD-SCID 
immunodeficient mice for the in vivo studies. The tumors were surgically 
removed and their weights and volumes were measured. Histological sections 
were made and analyzed by immunohistochemical methods for evaluation of 
blood and lymphatic vasculature. 
 
An additional objective was to establish and optimize cocultures of the 
examined cancer cell line and blood and lymphatic endothelial cells (BEC and 
LEC, respectively). This would allow a closer modeling of the paracrine 
interactions of these cells in vivo.  At the start of the study it was not clear what 
kind of cocultures would work with our research. One issue to solve was to try 
different combinations and find out proper conditions for our 2D and 3D 
cocultures between SW1222 cell line and lymphatic endothelial cells. 
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With the cocultures we wanted to study interactions of control and PROX1-
silenced cancer cells with endothelial cells (EC) in vitro in the presence of 
excess concentrations of VEGFs. More precisely the goal was to study how 
VEGFs contributed to the interactions between cancer cells and ECs, migration, 
mitogenesis, cytoskeleton morphology and formation of tubule like structures 
and if any effects of PROX1 could be detected in vitro. 
 
3D culture permits in vitro studies that resemble more the actual 
microenvironment events in vivo than does the regular 2D culture. In three 
dimensional cell cultures the cells are able to interact with each other and with 
the extracellular matrix in three dimensions. In 2D cultures the interaction is 
limited to laterally with each other and the underlying plastic petri dish, which 
does not efficiently model cell interaction in vivo. (1) Angiogenesis and 
lymphangiogenesis are complex processes with growth factor interactions and 
endothelial cell migration. Therefore 3D culture was the method of choice for in 
vitro studies. 
 
2 Review of the literature 
 
 
2.1 Colorectal cancer 
 
Colorectal cancer (CRC) is the second most common cause of cancer related 
death in developed countries. Incidence rate is also rapidly increasing in 
developing countries as standard of living grows. (2) Mutations in the intestinal 
crypt (stem) cells are the proximal drivers of colorectal adenocarcinomas (3).   
In most colorectal cancers the initiating event is an inactivation mutation of APC 
(adenomatous polyposis coli) protein in the APC/ß-catenin/TCF pathway (4, 5) 
A truncating mutation in the tumor suppressor APC gene induces the 
development colorectal polyps, which are benign overgrowths of the epithelial 
cells in the gut. These adenomas have a significantly elevated risk of 
progressing into malignant adenocarcinoma. This is well illustrated in patients 
with inherited loss of the one of the APC-genes. (4, 6) A person who suffers 
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from this condition, called familiar adenomatous polyposis (FAP) develops a 
large number of polyps at a very young age. FAP-diagnosis means almost 
certain development of colorectal cancer at some point in person’s life, and for 
this reason, the colon is usually removed from the patient. CRC is usually 
diagnosed when the patients are 35-40 years of age. (4, 7) It is estimated that 
5-10% of colorectal cancers are not sporadic.  Besides FAP, hereditary 
nonpolyposis colorectal cancer (HNPCC) known also as the Lynch syndrome is 
another common hereditary form of CRC. HNPCC patients have a mutation in a 
gene that codes for a component of the DNA mismatch repair system. A 
somatic mutation in the other functioning allele compromises the repair system. 
Malfunction in DNA mismatch repair system causes cell to develop mutations at 
an accelerated rate, which is the basis for the formation of HNPCC-associated 
cancers. (8) CRC generally progress in a designated manner where certain 
tumor suppressor genes and oncogenes mutate in an orderly fashion.  APC is 
called the gatekeeper gene in colorectal cancers since an inhibitory mutation of 
APC, activating the WNT signaling pathway, is the initiating event of CRC. 
Activating mutations of oncogenic K-RAS gene encoding a GTPase involved in 
transmitting growth signals commonly accompany APC mutation later on. 
Subsequent mutations in non-hypermutated CRCs occur in the TGF-ß/SMAD 
signaling pathway, as well as in the p53, PIK3CA, FBXW7, TCF7L2 and NRAS 
genes. (9, 10)  
 
2.2 The APC/ß-catenin/TCF pathway 
  
The APC/ß-catenin/TCF pathway is the so-called canonical pathway in WNT-
signaling.  One important signaling molecule of this pathway is the glycoprotein 
WNT3a that binds to a coreceptor complex at the plasma membrane. This 
consists of a frizzled family-protein and a low-density lipoprotein receptor-
related protein 5 or 6 (LRP-5/6).  The canonical WNT pathway signaling 
cascade connects to a multimeric protein complex inside the cell, known as the 
destruction complex, which consists of glycogen synthase kinase (GSK3), 
casein kinase (CKI), axin and APC. In the absence of a Frizzled/LRP-5/6-
receptor binding ligand, this destruction complex binds to ß-catenin, which 
allows GSK3 to phosphorylate ß-catenin. (11, 12) The phosphorylation of ß-
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catenin induces its ubiquitin-mediated proteolysis, whereby it is degraded. WNT 
binding to frz/LRP-5/6-receptor activates frizzled, which recruits the disheveled 
(Dvl) family protein in the cytoplasm.  Dvl is involved in the disassembly of the 
destruction complex, thus rescuing beta-catenin from degradation and allowing 
its accumulation in the cells. (12, 13) the thus accumulated ß-catenin is 
transported to the nucleus, where it complexes with transcription factors of the 
TCF/LEF-family. As a result, a transcription of multiple WNT regulated genes is 
activated. (11-13) In colorectal cancer, activation of the APC/ß-catenin/TCF 
pathway regulates cell differentiation, proliferation, apoptosis, migration and 
colorectal progenitor cell populations through the c-myc transcription factor (14, 
15). 
 
  
 
Figure 1. Activation and inactivation of the canonical WNT pathway(16). 
 
2.3 PROX1 
 
2.3.1 Discovery 
 
PROX1, whose homologue was first discovered in Drosophila as the Prospero 
gene, is an highly conserved homeobox transcription factor that regulates cell 
differentiation of many different organs in the embryo such as in the central 
nervous system (CNS), eye lens cells, pancreas, liver and heart. Prox1 deletion 
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in mouse embryos leads to developmental defects and death of the embryo 
before birth. (17) 
 
2.3.2 PROX1 in embryogenesis 
 
In the CNS PROX1 expression is activated through APC/ß-catenin/TCF 
pathway. Prox1 is necessary for the differentiation of neural stem cells in the 
adult hippocampus and initiation of neurogenesis (18). Expression of Prox1 
diminishes the neuronal progenitor cell pool by inducing cell differentiation. 
Sox1 regulates the extent of this cell pool by negatively regulating the rate of 
Prox1 expression.  (19) Prox1 can also inhibit Notch1 signaling, which leads to 
decreased neurogenesis (17). In the eye of mouse embryos Prox1 is 
responsible for lens fibers differentiation and elongation (20). Prox1 also 
regulates differentiation of progenitor cells in the retina (17). Also the liver and 
pancreas express Prox1 during embryonic development. Prox1 is responsible 
for hepatocyte migration to hepatic lobes in the development of the liver. Prox1 
knockout mice have prominently smaller sized liver and pancreas. (17) 
 
2.3.3 PROX1 in the development of lymphatic tissue 
 
PROX1 is responsible for lymphatic system development as it is essential for 
the differentiation of blood vascular endothelial cells to lymphatic endothelial 
cells (21-23). Mouse embryos where Prox1 has been deleted do not have 
lymph sacs or lymphatic vessels (24, 25). The differentiation of the lymphatic 
system begins when Sox18 induces the expression of Prox1 in the embryonic 
cardinal veins in mice (26).  Prox1 positive cells begin to show expression of 
VEGFR-3, LYVE-1 and other cell surface proteins specific for lymphatic 
endothelial cell identity. The VEGFR-3 is essential for proper 
lymphangiogenesis during embryonic development (27, 28). VEGF-C is 
secreted by nearby cells, binds to VEGFR-3 and establishes lymphatic 
endothelial cell sprouting from embryonic veins, promoting also lymphatic 
endothelial cell survival and proliferation (25). Prox1 is also required for 
maintaining the identity of differentiated lymphatic endothelial cells (23). 
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2.3.4 Role of PROX1 in cancer 
 
PROX1 is a tumor suppressor gene in many human cancers, such as certain 
brain tumors, hepatocellular carcinomas and cancer of the biliary duct. PROX1 
levels are suppressed in these cancer types (17).  Conversely in some cancers 
the role of PROX1 is quite the opposite and PROX1 actually shows oncogenic 
properties. For example, in colorectal cancer PROX1 levels increase 
considerably when compared to the normal intestine, where PROX1 expression 
is restricted to specific enteroendocrine cells and their progenitors. Indeed, 
PROX1 seems to promote the progression of intestinal adenomas to malignant 
CRC. PROX1 expression seems to modulate cytoskeletal organization and to 
decrease the adhesion of the cells to pericellular structures. This may contribute 
to tumor progression induced by PROX1.  In fact, PROX1 is a target gene of the 
TCF/ß-catenin-pathway, which is overactivated in most colorectal cancers. (29)  
The significance of PROX1 in CRC has been proposed to be associated with 
the tumor’s ability to metastasize. Here one should note that PROX1 also plays 
a role in the lymphatic system, which provides one major route of metastatic 
spread. (17) 
 
2.4 The VEGF Family 
 
There are several families of growth factors and their receptor protein tyrosine 
kinases that regulate angiogenesis. These include angiopoietin/Tie, ephrin/Eph, 
fibroblast growth factor/FGF receptor families as well as the most intensively 
studied angiogenic ligand/receptor family, the VEGFs and VEGFRs. The 
members of the VEGF family are secreted glycoproteins and the family consists 
of VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placenta growth factor (PIGF) (30, 
31). There are also VEGF homologues known as VEGF-E (produces by Orf-
viruses) and VEGF-F (found in snake venom) (31). 
 
 7 
 
 
2.5 VEGF-A 
 
2.5.1 Effects of VEGF-A on endothelial cells 
 
VEGF-A is the major growth factor involved in vasculogenesis in embryos and 
angiogenesis in both embryos and in adults. Paracrine VEGF-A activates 
angiogenesis by promoting the proliferation, migration, specialization, and 
survival of endothelial cells. VEGF-A also has a role creating fenestrae in the 
endothelium and it promotes endothelial permeability to plasma proteins in vivo. 
(32) VEGF-A mediates these effects on the endothelial cells mainly through 
VEGF receptor 2 (VEGFR-2). (31-33) VEGF-A also binds to VEGFR-1, which 
does not directly activate angiogenesis in most settings.  (31, 34, 35) Besides 
ECs, VEGFR-1 is also expressed in some other cell types, such as 
macrophages, where its activation is needed cell migration in chemotaxis 
towards VEGF-A(31). Hypoxia is the strongest inducer of VEGF-A expression. 
In hypoxic conditions hypoxia-inducible transcription factor 1 binds to the VEGF-
A gene and the levels of this otherwise fast-degraded protein are stabilized. 
VEGF-A expression is also induced by TGF-ß, FGF-2, Il-1ß and Il-6.(34, 36) 
 
 
2.5.2 Activation of VEGF receptor 
 
VEGF receptors have tyrosine kinase activity. When VEGF-A binds to VEGFR-
2 on the receptor at the plasma membrane, the receptor undergoes 
dimerization, which induces the trans- or autophosphorylation of tyrosine 
residues in the cytoplasmic part of the receptor.  Phosphorylation of tyrosine 
residues generates a docking site for mediator phospholipase C gamma (PLC 
γ) and certain other proteins. PLCγ hydrolyzes PIP2 (phosphatidylinositol), 
which releases DAG (diacylglycerol) and IP3 (inositol 1,4,5-triphosphate), these 
act as second messengers (37). 
Rise in intracellular IP3 concentration results in the rise of intracellular calcium. 
DAG in turn in corporation with the risen intracellular calcium possibly activates 
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RAS/RAF/ERK/MAPK pathway through PKC (protein kinase C).  This Map 
kinase pathway ends in the expression of genes inducing the proliferation of 
endothelial cells. Survival of the endothelial cells is in part promoted through the 
PKB/AKT pathway activated by VEGFR-2. (37) In addition to VEGFR-1 and 
VEGFR-2, VEGF-A also binds to other class of receptors known as neuropilins 
(NRP). NRP-1 improves VEGF-A binding to VEGFR-2 and it is thought that 
NRP-1 is a coreceptor for VEGF-A in angiogenesis. (32, 35)  
 
2.5.3 VEGF-A in embryogenesis 
 
VEGF-A has a major role in embryonic vasculogenesis. Embryos lacking one 
VEGF-A allele die due to dysfunctional formation of blood vessels. (31, 36)   
VEGF-A is also important postnatally as it is required for the body growth, organ 
development and endochondral bone formation.(36) 
 
 
2.5.4 Physiological effects of VEGF-A  
 
In adults, low levels of VEGF-A are produced in almost every tissue of the 
human body(34). It is commonly known that VEGF-A has an angiogenic role in 
wound healing(30, 32, 34-36). VEGF-A also facilitates the bone repair process. 
In addition, VEGF-A has other important roles in blood vessel regulation. 
Increased VEGF-A is expressed in skeletal muscles after exercise and vascular 
growth is to some extent associated with physiological muscle hypertrophy. In 
females, VEGF-A mediates angiogenesis in the female reproductive system 
such as in the breast, uterus and ovaries. (34) Newly formed vessels in adults 
also are dependent of stimulation by VEGF-A and without sufficient blood flow 
or VEGF they will degenerate(34, 35).   
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2.5.5 VEGF-A in disease 
 
Dysregulation of VEGF-A expression is a contributing factor in many 
pathological conditions in adults. These include atherosclerosis, diabetic 
retinopathy, psoriasis, and age-related macular degeneration.  Overactivation of 
angiogenesis is an important hallmark of cancer. (34) VEGF-A plays a strong 
role in tumor growth. Depletion of VEGF-A from mouse xenografts reduces 
tumor growth and vice versa, overexpression of VEGF-A accelerates tumor 
growth. (36) Recent studies suggest that VEGF-A has a distinct role in neuronal 
development. VEGF-A induces neuronal migration, survival, axon guidance and 
neural stem cell differentiation to neurons or neurogenesis.(38) 
   
2.5.6 VEGF-A isoforms 
 
There exists four different isoforms of the VEGF-A: VEFG-A121, VEGF-A145, 
VEGF-A165 and VEGF-A189, which are produced by alternative pre-mRNA 
splicing. The isoforms differ by their ability to bind to heparin sulfate 
proteoglycans. Due to differences in their binding affinities, they are thought to 
localize heterogeneously around the secreting cells. The heparin-binding 
domains regulate differences in the affinities to VEGF cell surface receptors. 
Functionally different isoforms of VEGF-A regulate the vascular network pattern, 
including vessel size, quality and number of branches.(32) 
 
2.6 VEGF-C 
 
VEGF-C is made as a precursor protein, which undergoes proteolytic 
processing to gain receptor-activating properties. Its pro-form binds to VEGFR-
3(39); this is then processed by a metalloprotease-CCBE1 protein complex to 
activate the signal transduction(40). The proteolytically processed short form of 
VEGF-C, which is proteolytically from the pro-VEGF-C, shows affinity also to 
VEGFR-2 (28) and to a soluble for of VEGFR-2 (sVEGFR-2) (37). sVEGFR-2 
can compete with VEGFR-2 for VEGF-C binding, which inhibits the proliferation 
of lymphatic endothelial cells(37). VEGF-C is shown to interact with NRP-2 in 
addition to VEGFR-3. NRP-2 and VEGFR-3 might have coreceptor properties in 
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similar way as VEGF-A and NRP-1. (17) VEGFR-3 is highly expressed in 
lymphatic endothelium and VEGF-C induces lymphatic vessel growth through 
this receptor. (28, 36, 39) VEGFR-3 activation is needed for the survival and 
migration of the lymphatic endothelial cells destined for lymphatic vessel 
formation. Naturally, activation of VEGFR-3 also promotes lymphangiogenesis. 
VEGF-C is essential for the development of lymphatic vessels as mice with both 
deleted alleles of VEGF-C gene die before birth from developmental faults of 
the lymphatic system. (28)  
 
2.7 VEGF-D 
 
VEGF-D is also a ligand of VEGFR-2 and VEGFR-3. VEGF-D can promote 
blood vascular endothelial cell mitogenesis and thus angiogenesis. VEGF-D 
also promotes migration and survival of lymphatic endothelial cells through 
VEGFR-3-induced lymphangiogenesis. (36) VEGF-D is not as important as 
VEGF-C in embryonic development as its deletion causes only minor lymphatic 
defects in embryos(25, 41). 
 
2.8 VEGF-B 
 
Heart, skeletal muscle and brown fat and vascular smooth muscle show 
expression of VEGF-B. VEGF-B binds only to VEGFR-1 and NRP-1 and it is 
poorly angiogenic.  (31, 42) Overexpression of VEGF-B in the heart leads to 
cardiomyocyte hypertrophy and changes in mitochondrial and lipid metabolism. 
This indicates that VEGF-B has as yet poorly studied, but interesting and 
unusual functions for a member of the VEGF family.(42) 
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Figure 2. VEGF growth factors and their binding to VEGF receptors (43). 
 
2.9 RNA interference  
 
RNA interference is a mechanism in which short strands of RNA known as 
microRNAs (miRNA) can regulate mRNA stability and translation. MiRNAs have 
a nucleotide sequence that is complementary to their target mRNAs. 
Transfection of short hairpin RNAs (shRNAs) is a mechanism for long lasting 
silencing of target genes. A vector (e.g. lentivirus) encoding the desired shRNA 
structure is introduced into target cells. The lentiviral vector integrates the 
shRNA gene into the genome of the target cell. The transcribed double-
stranded shRNA is transported out of the nucleus by exportin and processed by 
the dicer enzyme in the cytoplasm.  The processed shRNA binds to the so-
called RNA-induced silencing complex (RISC). In the RISC, a family of 
argonaute proteins (Ago) catalyzes the recognition of the target mRNA 
complementary to the sequence of the shRNA. The RISC with its attached 
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shRNA binds to the target mRNA and two alternative events may occur. Either 
a type of Ago protein acts as an endonuclease protein and cleaves the target 
mRNA or RISC-shRNA complex suppresses the translation of the mRNA. Both 
events “silence” the translation of the target gene’s protein.(44) 
 
 
3 Materials and methods 
 
 
3.1 Cells  
 
In this research project, we mainly used a previously made stable clone of the 
SW1222 CRC cells that expresses high amounts of PROX1. The SW1222 cell 
line is commonly used in laboratories and it is originally derived from a relatively 
differentiated human colorectal adenocarcinoma that can form glandular 
structures in 3D cultures(45) 
 
Lentiviruses were used for gene transfers to produce additional populations of 
the SW1222 cells as shown. (Table 1.) 
 
shPROX1 + VEGF-A 
 
SCR + VEGF-A 
shPROX1 + Luc SCR + Luc 
 
Table 1.  Different SW1222 cell lines created by lentiviral gene transduction 
 
VEGF-A means the overexpression of VEGF-A gene. Luc stands for luciferase 
and it was used as a control for VEGF-A gene. ShPROX1 stands for small 
hairpin silenced PROX1 gene. Scrambled (SCR) small hairpin was used as a 
control for shPROX1. 
 
Together with my collaborator, Ville Hyvönen, we cultured also BECs and LECs 
using published methods(46). 
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3.2 Gene transduction 
 
Lentivirus vectors with VSVG-surface protein were used for gene transfers. 
Although the vectors are unable to replicate, they are capable of gene 
transduction into human cells. Lentiviral work was performed in Biosafety level 2 
cell culture room to avoid contamination.  
 
Lentiviruses transfer their genes to fairly random parts of the cell genome. 
Lentivirus constructs containing the VEGF-A gene and shPROX1 gene were 
produced by others. Transductions were performed by adding 10-40 x 106 
particles/ml of concentrated viral vector to recently subcultured cells. 
Approximately 8 µg/ml polybrene was added to enhance the transduction rate. 
Polybrene decreases the electric repulsion between the target cells and the 
virus particles, which is thought to increase the viruses’ penetration rate. The 
viral vectors were let to infect the cancer cells for approximately 24 hours. 
 
In addition to the examined genes, the lentivirus constructs also included gene 
encoding the enhanced green fluorescent protein (EGFP), which is a widely 
used gene to mark successfully transduced cells.  Cells where the EGFP gene 
has integrated into host DNA produce the EGFP protein, which can be 
observed in a fluorescent microscope. Expression and silencing of the desired 
proteins was verified by immunofluorescence staining with antibodies against 
VEGF-A and PROX1, respectively.  
 
3.3 Cell culture 
 
Cells were cultured on sterile cell culture plates in an incubator set at 37 ℃, 
equipped with a humidified atmosphere containing 5% carbon dioxide. We used 
the high glucose (4,5g/l) DMEM-medium (Lonza) supplemented with L-
glutamine (Sigma) 10% Fetal Bovine serum (Gibco), 1,0ml penicillin + 
streptomycin for the cell culturing. Cells were subcultured approximately 3 times 
a week and 70 % confluence. 
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LECs and BECs were cultured in Endothelial Cell Basal Medium MV 
(PromoCell) supplemented with L-glutamine (Sigma), 10% fetal bovine serum 
(Gibca), penicillin + streptomycin and fungizone. Also 100 ng/ml VEGF-C was 
added to LEC endothelial medium in order to induce LEC proliferation. LEC and 
BECs were incubated in 37℃ with 5% carbon dioxide. LECs and BECs used in 
cocultures were in cell passage 3 or 4. 
 
3.4 Subculturing of cells 
 
The culture medium was removed from the plate and the plates were then 
washed quickly with PBS or trypsin in order to get rid of remaining fetal calf 
serum that can inhibit trypsin. The cells were incubated in 0,05% trypsin/PBS. 
1-7ml of trypsin was added to the cell plates depending on the size of the plate. 
The function of trypsin is to cleave cell adhesion molecules attaching the cells 
each other and the plate so that the cells can be detached. The trypsin 
incubation in 37℃, 5%CO2 was for 45-60 minutes for SW1222 cells and 2 
minutes for LECs and BECs.  
 
After the incubation, the cells were extracted from the culture plates by pipetting 
them back and forth repeatedly. This mechanic force detaches the cells from 
each other.  Microscope was used to check that the cells were detached from 
the plate surface and separated. The trypsin solution containing the cells was 
transferred to falcon tubes and centrifuged 1500 rpm for 5 minutes in order to 
pellet the cells to the bottom of the tube.  
 
The supernatant containing the trypsin was removed from top of the pellet with 
pipet. Pellet was resuspended in additional medium. The medium that 
contained the cells was divided to different plates in convenient proportion. The 
cells were then suspended to new medium, which was added to plates and the 
plates were shaken slightly to spread cells evenly on the plate.  
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3.5 Cocultures of tumor cells with endothelial cells 
 
In vitro cocultures were established between SW1222 carcinoma cells and 
LECs or BECs in order to examine the effect of VEGF overexpression in the 
PROX1 silenced SW1222-cells. In addition to 2D cocultures, 3D cocultures 
were established by culturing cells on top of the Geltrex™-matrix, which gave 
the best results among the ones tried. 
  
Geltrex is composed of extracellular basement membrane matrix purified from 
Engelbreth-Holm-Swarm (EHS) tumors. Growing cells on top of basement 
membrane resembles better the in vivo interactions between cells than the 
regular 2D cultures. 
 
3D cocultures were carried out in the BD BioCoat™ matrigel™ invasion 
chamber (BD biosciences). Cells were detached from plates and counted. 
Medium containing the appropriate amount of SW1222 cells and LECs was 
combined, diluted to 1 ml of endothelial medium and seeded to a chamber. 10 
000 SW1222 cells and 50 000 LECs were used for one chamber. The cells in 
the cocultures were allowed to proliferate for 2 days, after which they were 
imaged with an axiovert microscope. The actin cytoskeleton was then stained 
with fluorescent phalloidin and imaged in a confocal microscope. 
 
2D cocultures were established in regular 48-well plates with 4000 SW1222 
cells and 20 000 LECs. They were imaged in the fluorescence and confocal 
microscopes after phalloidin and Pecam-1 staining. 
 
 
3.6 Immunofluorescent staining of coverslips 
 
Cells were subcultured with plating into 12-well plate containing coverslips and 
allowed to attach overnight. They were then fixed with 4 % paraformaldehyde 
(PFA) for 10 minutes, washed with PBS three times for five minutes. Plasma 
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membranes of the cells were made permeable to antibodies with detergent 
0,1% TritonX100 in PBS solution. The blocking solution, made of 1% BSA 
(bovine serum albumin) in PBS, was also introduced to the cells at the same 
time. The function of the blocking solution is to prevent nonspecific binding of 
the antibody and thus decrease background noise in the staining. The cells 
were incubated for 15 minutes in these solutions.  
 
The primary antibody attaches to the proteins of interest. Primary antibodies 
were diluted in 1% BSA-PBS solution.  The PROX1 antibody (made in goat, 
R&D) was applied at 0,5 ug/ml, VEGF-A antibody (made in goat, R&D) was 
0,025 ug/ml. Pecam-1 (antibody against CD31, made in Rat, BD biosciences), 
which attaches to endothelial cells, was 1,25 ug/ml 
 
Primary antibodies were introduced to the cells and incubated for 60 minutes. 
After the incubation, unbound antibody was washed out with PBS, 3 times for 5 
minutes. 
 
Secondary antibodies, also diluted in 1% BSA-PBS, were centrifuged at 
+4°C with 14 000 rpm for 9 minutes.  We used antibody against goat (made in 
donkey, life technologies A11058) applied at  4 ug/ml. 
 
Secondary antibody is a protein against the primary antibody and therefore it 
attaches to the primary antibody. Fluorescent molecule is attached to the 
secondary antibody consequently antibody-complex can be seen with the 
immunofluorescent microscope. The washes were done as above. 
 
We also used conjugated Texas Red-X Phalloidin (Life Technologies). 
Phalloidin is a mushroom toxin that binds to F-actin molecules inside cells. 
Fluorescent Texas Red-X is conjugated to phalloidin. Texas Red-X Phalloidin 
was applied at 0,4 units/ml in 1%BSA-PBS and incubated for 30 minutes. 
 
Coverslips were then carefully removed from well plates and transferred to 
microscope slides on top of a drop of Vectashield mounting medium containing 
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DAPI, a staining color that binds to DNA and can be observed under proper UV-
light illumination in a fluorescence microscope. 
 
3.7 Mouse xenograft experiments 
 
For tumor xenograft modeling, we used immunodeficient Nod scid gamma 
(NSG) mice, which lack mature B cells, T cells and functional NK cells. In order 
to injected cancer cells to survive and form tumors, the rodents’ immune system 
must be compromised so that it will not eliminate foreign cells. 
 
Cells were resuspended to geltrex for injections after splitting and counting.  We 
injected cells subcutaneously, one cell line to other side and its control to the 
other side. Overall, 6 mice were used and 1,5 million cells/injection. The mice 
were anesthetized before the injections. Of note, all work with mice was done 
by or in the presence of my instructor Ville Hyvönen, who has the appropriate 
training and licenses for working with mice. 
 
Mice were put to sleep by anesthetics and the tumors were surgically removed 
from the mice after 14 days. Tumors were weighed and their diameter was 
measured before the tumors samples were embedded in paraffin for overnight. 
Tumor samples were then sectioned to thin sections. Sections were stained for 
E-cadherin  (2 ug/ml dilution, made in mouse, Abcam) and Endomucin (2,5 
ug/ml dilution, made in rat, R&D)  
 
Most of the stainings and analysis of the tumor sections were done by Ville 
Hyvönen after my collaboration with the project ended. 
 
3.8 Immunofluorescent staining of paraffin sections 
 
Paraffin sections were deparaffinized and rehydrated by the following 
procedure.  Sections were incubated in xylen for 5 minutes 3 times, in absolute 
EtOH for 2 minutes 2 times, in 95% EtOH for 2 minutes 2 times, in 70% EtOH 
for 2 minutes 1 time and rehydrated with deionized water for 4 minutes 2 times. 
Sections were then boiled in microwave for 15 minutes in pH 9 antigen retrieval 
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solution diluted 1:10 in ionized water and washed with PBS afterwards. 
Sections were incubated in 0,1% TritonX100 and blocking solution made of 1% 
BSA for 30 minutes. Primary antibodies diluted in blocking solution were added 
on Sections were incubated with primary antibodies overnight at +4 ℃. On the 
next day sections were washed 3 times for 5 minutes with TNT washing buffer 
(0,1 M Tris pH7,4, 0,15 M NaCl, 0,05% Tween 20) Sections were then 
incubated with the respective species specific fluorescent secondary antibodies 
(4 ug/ml, Life technologies) for 1 hour. After incubation sections were washed 
with TNT 3 times, once with water, and mounted with mounting media with 
DAPI to visualize cell nuclei (Vectashield). 
 
3.9 Imaging 
 
Immunofluorescence pictures were taken with Zeiss Axioplan 2-epifluorescence 
microscope and non-fixed co-cultures were imaged with Zeiss Axiovert 200 
inverted epifluorescence microscope. This microscope transmits ultraviolet light 
that can excite electrons of the sample. Fluorescent proteins emit light 
depending on the wavelength of the exciting UV-light. Different filters were used 
to separate different fluorescent proteins.  FITC filter was used for both DAPI-
nuclear staining and EGFP. Alexa 594 was used for fluorescent antibodies.  
Confocal images were taken with Zeiss LSM 780. 
 
3.10 Statistical analysis 
 
Statistical comparison of two groups was done by two-tailed paired t-test using 
Microsoft excel. The Statistical significance is marked by *p<0,05 and 
***p<0,005. 
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4 Results 
 
 
4.1 Effect of VEGF-A in in vitro cocultures 
 
As expected, in 3D cocultures with VEGF-A overexpressing SW1222 cells, 
LECs were clearly more organized into tubules and formed connections 
between the colorectal cell colonies. In the control cultures, the LECs formed 
web-like structures around the cancer cell colonies and tubule formation was 
less clear (Figs. 3 and 4). Cocultures of SW1222 cells with BECs showed a 
similar tube formative response to VEGF-A (Fig. 5). 
Figure 3. Phase contrast images of SW1222/LEC 3D cocultures. 
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Figure 4. Confocal image of 3D SW1222/LEC cells (green) in coculture with 
LECs; phalloidin staining in red. 
Figure 5.  Phase contrast images of the SW1222/BEC 3D cocultures. 
V
EG
FA
	
Lu
c	
Phalloidin	 EGFP	 Merged	/w	DAPI	x10	
SC
R
	
sh
P
R
O
X
1
	
LUC	 VEGF-A	x10	
 21 
 
 
PROX1 silencing did not affect tubule formation in the presence of VEGF-A 
(Figs. 3 and 5). No difference was observed between the cocultures with 
PROX1 silenced or control SW1222 cells. 
 
We noticed that VEGF-A overexpressing CRC colonies were larger than their 
controls in the 3D cocultures with LECs. (Fig. 6) This was also true when the 
BECs were used (Fig. 7). 
 
Figure 6.  Phase contrast images of the SW1222/LEC 3D cocultures 
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Figure 7.  High-power magnification of the SW1222/BEC 3D cocultures. 
 
We did not find any difference between the cell lines in 2D cocultures with LECs 
(data not shown). The LECs and SW1222 cells were both proliferated in these 
cultures, but in contrast to the matrigel cultures, the LECs were located around 
the cancer cells randomly without organized structures. Based on results with 
LECs we did not study 2D cocultures with BECs. 
 
4.2 Effect of VEGF-A in tumor xenografts 
 
As can be seen in Fig. 8, the SCR-VEGF-A tumors were significantly larger than 
the SCR-Luc tumors. The shPROX1-LUC tumors were also smaller than the 
control SCR-LUC tumors. There was no statistically significant difference 
between the weight of the shPROX1-VEGF-A and SCR-LUC tumors. 
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Figure 8. (A) Average weights of the xenotransplant tumors made of transfected 
SW1222 cells (the standard error of the mean and statistical significance is 
indicated). (B) Volumes of the respective tumors.  
 
VEGF-A overexpressing tumors were significantly more densely vascularized 
than their controls as expected. VEGF-A overexpression induced angiogenesis 
in the PROX1 silenced tumors. PROX1 silencing decreased angiogenesis 
compared to scrambled shRNA. (Figs. 9 & 10) 
 
The PROX1 silenced tumors showed a greater area of necrosis in the core of 
the tumors even with VEGF-A overexpression (Fig. 11). 
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Figure 9. Average relative blood vessel area / number of cancer cells in 
comparable tumor areas. 
 
 
Figure 10. Endomucin/E-cadherin/Dapi staining of tumor sections. 
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Figure 11. Histology image of tumor sections. 
 
5 Discussion 
 
 
Our study suggests that overexpression of VEGF-A increases the growth of the 
tumor xenografts in terms of tumor weight during a 14 day follow-up. 
Interestingly, even though the overexpression of VEGF-A increased the 
vascularity of the PROX1 silenced tumors, the core of the shPROX1 tumors still 
showed a larger necrotic area. In fact, further studies have recently shown that 
PROX1 helps the cells to adapt against hypoxia by promoting autophagy (49).  
 
In the in vitro studies we found out that PROX1 silencing did not stop lymphatic 
endothelial cells or blood endothelial cells from forming structured tubules, 
which is an indication of lymphangiogenic activity.  This observation in vitro 
correlates directly with the in vivo results where PROX1 silencing did not inhibit 
tumor angiogenesis when VEGF-A was overexpressed.  
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The intriguing observation that colorectal cancer cell colonies were bigger in 
cocultures with excess of VEGF-A could have engendered a project to find out 
what signaling molecules are involved in the cross-talk between the LECs and 
cancer cells. Indeed, a paper with a finding that endothelial cells secrete soluble 
Jagged-1 that promotes colorectal cancer stem cells via Notch was published in 
early 2013 (47). 
 
During my project, I also made a SW1222 cell line with VEGF-C overexpression 
similar to the VEGF-A overexpression. In vitro studies with the VEGF-C 
transfected SW1222 cells showed a similar LEC tube formation as VEGF-A 
(data not shown). A continuation to this project would mean repeating the same 
in vivo experiment with VEGF-C instead of VEGF-A. VEGF-C expression 
induces tumor metastasis and progression, whereas VEGF-C downregulation 
inhibits tumor growth and metastasis, depending on the tumor type (48). It 
would be interesting to see how VEGF-C overexpression influences the 
xenografts in relation to PROX1-silencing. It would be also interesting to study 
VEGF-C overexpression, PROX1 silencing and its expected antagonistic effect 
on tumor metastasis. 
 
One potential problem in our study was the mediocre rate of PROX1 silencing. 
Gene transduction rate is seldom perfect: Furthermore, we did not have a gene 
construct with a good selection marker (e.g. antibiotic resistance gene for 
antibiotic selection) to accomplish very strong shPROX1 rate in the transfected 
cells.  Furthermore, the PROX1 silenced cells slowly tend to be selected out by 
the survival of the fittest in cell culture, which further reduces the population of 
PROX1 silenced cells. This might have reduced the contrast between the SCR 
and PROX1 transfected cells in our experiments. 
 27 
 
 
 
 
 
References  
 
1. Pampaloni F, Reynaud EG, Stelzer EH. The third dimension bridges the gap 
between cell culture and live tissue. Nature Reviews Molecular Cell Biology. 
2007 Oct;8(10):839-45. 
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer 
statistics. CA: a Cancer Journal for Clinicians. 2011 Mar-Apr;61(2):69-90. 
3. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den 
Born M, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature. 
2009 Jan 29;457(7229):608-11. 
4. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 
1996 Oct 18;87(2):159-70. 
5. Skog M, Bono P, Lundin M, Lundin J, Louhimo J, Linder N, et al. Expression 
and prognostic value of transcription factor PROX1 in colorectal cancer. Br J 
Cancer. 2011 Oct 25;105(9):1346-51. 
6. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 
2006 Nov 3;127(3):469-80. 
7. Galiatsatos P. Familial adenomatous polyposis. Am J Gastroenterol. 
2006;101(2):385-98. 
8. Lynch HT, Lynch JF. Lynch syndrome: History and current status. Dis 
Markers. 2004;20(4-5):181-98. 
9. Arends JW. Molecular interactions in the vogelstein model of colorectal 
carcinoma. J Pathol. 2000 Mar;190(4):412-6. 
10. Cancer Genome Atlas N. Comprehensive molecular characterization of 
human colon and rectal cancer. Nature. 2012 Jul 19;487(7407):330-7. 
11. McDonald SL, Silver AR. On target? strategies and progress in the 
development of therapies for colorectal cancer targeted against WNT signalling. 
Colorectal Disease. 2011 Apr;13(4):360-9. 
 28 
12. Maruotti N, Corrado A, Neve A, Cantatore FP. Systemic effects of wnt 
signaling. J Cell Physiol. 2013 Jul;228(7):1428-32. 
13. Rao TP, Kuhl M. An updated overview on wnt signaling pathways: A 
prelude for more. Circ Res. 2010 Jun 25;106(12):1798-806. 
14. Sansom OJ, Reed KR, Hayes AJ, Ireland H, Brinkmann H, Newton IP, et al. 
Loss of apc in vivo immediately perturbs wnt signaling, differentiation, and 
migration. Genes Dev. 2004 Jun 15;18(12):1385-90. 
15. Sansom OJ, Meniel VS, Muncan V, Phesse TJ, Wilkins JA, Reed KR, et al. 
Myc deletion rescues apc deficiency in the small intestine. Nature. 2007 Apr 
5;446(7136):676-9. 
16. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell. 2012 Jun 
8;149(6):1192-205. 
17. Elsir T, Smits A, Lindstrom MS, Nister M. Transcription factor PROX1: Its 
role in development and cancer. Cancer & Metastasis Reviews. 2012 Dec;31(3-
4):793-805. 
18. Karalay O, Doberauer K, Vadodaria KC, Knobloch M, Berti L, 
Miquelajauregui A, et al. Prospero-related homeobox 1 gene (Prox1) is 
regulated by canonical wnt signaling and has a stage-specific role in adult 
hippocampal neurogenesis. Proc Natl Acad Sci U S A. 2011 Apr 
5;108(14):5807-12. 
19. Elkouris M, Balaskas N, Poulou M, Politis PK, Panayiotou E, Malas S, et al. 
Sox1 maintains the undifferentiated state of cortical neural progenitor cells via 
the suppression of Prox1-mediated cell cycle exit and neurogenesis. Stem 
Cells. 2011 Jan;29(1):89-98. 
20. Wigle JT, Chowdhury K, Gruss P, Oliver G. Prox1 function is crucial for 
mouse lens-fibre elongation. Nat Genet. 1999 Mar;21(3):318-22. 
21. Harvey NL, Srinivasan RS, Dillard ME, Johnson NC, Witte MH, Boyd K, et 
al. Lymphatic vascular defects promoted by Prox1 haploinsufficiency cause 
adult-onset obesity. Nat Genet. 2005 Oct;37(10):1072-81. 
22. Petrova TV, Makinen T, Makela TP, Saarela J, Virtanen I, Ferrell RE, et al. 
Lymphatic endothelial reprogramming of vascular endothelial cells by the prox-1 
homeobox transcription factor. EMBO J. 2002 Sep 2;21(17):4593-9. 
23. Oliver G, Srinivasan RS. Endothelial cell plasticity: How to become and 
remain a lymphatic endothelial cell. Development. 2010 Feb;137(3):363-72. 
24. Tammela T, Alitalo K. Lymphangiogenesis: Molecular mechanisms and 
future promise. Cell. 2010 Feb 19;140(4):460-76. 
 29 
25. Adams RH, Alitalo K. Molecular regulation of angiogenesis and 
lymphangiogenesis. Nature Reviews Molecular Cell Biology. 2007 Jun;8(6):464-
78. 
26. Francois M, Caprini A, Hosking B, Orsenigo F, Wilhelm D, Browne C, et al. 
Sox18 induces development of the lymphatic vasculature in mice. Nature. 2008 
Dec 4;456(7222):643-7. 
27. Tammela T, Petrova TV, Alitalo K. Molecular lymphangiogenesis: New 
players. Trends Cell Biol. 2005 Aug;15(8):434-41. 
28. Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, et al. 
Vascular endothelial growth factor C is required for sprouting of the first 
lymphatic vessels from embryonic veins. Nat Immunol. 2004 Jan;5(1):74-80. 
29. Petrova TV, Nykanen A, Norrmen C, Ivanov KI, Andersson LC, Haglund C, 
et al. Transcription factor PROX1 induces colon cancer progression by 
promoting the transition from benign to highly dysplastic phenotype. Cancer 
Cell. 2008 May;13(5):407-19. 
30. Roskoski R,Jr. Vascular endothelial growth factor (VEGF) signaling in tumor 
progression. Critical Reviews in Oncology-Hematology. 2007 Jun;62(3):179-
213. 
31. Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in 
angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol. 2009 
Apr;21(2):154-65. 
32. Ruhrberg C. Growing and shaping the vascular tree: Multiple roles for 
VEGF. Bioessays. 2003 Nov;25(11):1052-60. 
33. Clauss M. Molecular biology of the VEGF and the VEGF receptor family. 
Seminars in Thrombosis & Hemostasis. 2000;26(5):561-9. 
34. Maharaj AS, D'Amore PA. Roles for VEGF in the adult. Microvasc Res. 
2007 Sep-Nov;74(2-3):100-13. 
35. McColl BK, Stacker SA, Achen MG. Molecular regulation of the VEGF family 
-- inducers of angiogenesis and lymphangiogenesis. APMIS. 2004 Jul-
Aug;112(7-8):463-80. 
36. Holmes DI, Zachary I. The vascular endothelial growth factor (VEGF) family: 
Angiogenic factors in health and disease. Genome Biol. 2005;6(2):209. 
37. Koch S, Claesson-Welsh L. Signal transduction by vascular endothelial 
growth factor receptors. Cold Spring Harbor Perspectives in Medicine. 2012 
Jul;2(7):a006502. 
38. Mackenzie F, Ruhrberg C. Diverse roles for VEGF-A in the nervous system. 
Development. 2012 Apr;139(8):1371-80. 
 30 
39. Enholm B, Jussila L, Karkkainen M, Alitalo K. Vascular endothelial growth 
factor-C: A growth factor for lymphatic and blood vascular endothelial cells. 
Trends Cardiovasc Med. 1998 Oct;8(7):292-7. 
40. Jeltsch M, Jha SK, Tvorogov D, Anisimov A, Leppanen VM, Holopainen T, 
et al. CCBE1 enhances lymphangiogenesis via a disintegrin and 
metalloprotease with thrombospondin motifs-3-mediated vascular endothelial 
growth factor-C activation. Circulation. 2014 May 13;129(19):1962-71. 
41. Haiko P, Makinen T, Keskitalo S, Taipale J, Karkkainen MJ, Baldwin ME, et 
al. Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is 
not equivalent to VEGF receptor 3 deletion in mouse embryos. Molecular & 
Cellular Biology. 2008 Aug;28(15):4843-50. 
42. Karpanen T, Bry M, Ollila HM, Seppanen-Laakso T, Liimatta E, Leskinen H, 
et al. Overexpression of vascular endothelial growth factor-B in mouse heart 
alters cardiac lipid metabolism and induces myocardial hypertrophy. Circ Res. 
2008 Oct 24;103(9):1018-26. 
43. Testa U, Pannitteri G, Condorelli GL. Vascular endothelial growth factors in 
cardiovascular medicine. J Cardiovasc Med. 2008 Dec;9(12):1190-221. 
44. Rao DD, Vorhies JS, Senzer N, Nemunaitis J. siRNA vs. shRNA: 
Similarities and differences. Adv Drug Deliv Rev. 2009 Jul 25;61(9):746-59. 
45. Richman PI, Bodmer WF. Control of differentiation in human colorectal 
carcinoma cell lines: Epithelial-mesenchymal interactions. J Pathol. 1988 
Nov;156(3):197-211. 
46. Karkkainen MJ, Makinen T, Alitalo K. Lymphatic endothelium: A new frontier 
of metastasis research. Nat Cell Biol. 2002 Jan;4(1):E2-5. 
47. Lu J, Ye X, Fan F, Xia L, Bhattacharya R, Bellister S, et al. Endothelial cells 
promote the colorectal cancer stem cell phenotype through a soluble form of 
jagged-1. Cancer Cell. 2013 Feb 11;23(2):171-85. 
48. Khromova N, Kopnin P, Rybko V, Kopnin BP. Downregulation of VEGF-C 
expression in lung and colon cancer cells decelerates tumor growth and inhibits 
metastasis via multiple mechanisms. Oncogene. 2012 Mar 15;31(11):1389-97. 
49. Wiener Z, Högström J, Hyvönen V, Band A, Kallio P, Holopainen T, Dufva 
O, Haglund C, Kruuna O, Guillermo O, Ben-Neriah Y, Alitalo K. Cell Reports 
2014 *This article has been accepted but not published at the time of writing 
this paper 
 
 
 
